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Abstract
Only a small percentage of patients with Alzheimer's disease benefit from current drug therapy and
for only a relatively short time. This is not surprising as the goal of these drugs is to enhance existing
cerebral function in Alzheimer patients and not to block the progression of cognitive decline. In
contrast, immunotherapy is directed at clearing the neurotoxic amyloid beta peptide from the brain
that directly or indirectly leads to cognitive decline in patients with Alzheimer's disease. The single
trial of active immunization with the amyloid beta peptide provided suggestive evidence of a
reduction in cerebral amyloid plaques and of stabilization in cognitive function of half the patients
who developed good antibody responses to the amyloid beta peptide. However, 6% of actively
immunized Alzheimer patients developed sterile meningoencephalitis that forced the cessation of
the clinical trial. Passive immunotherapy in animal models of Alzheimer's disease has provided
similar benefits comparable to those seen with active immunotherapy and has the potential of being
effective in the half of Alzheimer's disease patients who do not make a significant anti-amyloid beta
peptide antibody response and without inducing T-cell-mediated encephalitis. Published studies of
5 patients with sporadic Alzheimer disease treated with intravenous immunoglobulin containing
anti-amyloid beta peptide antibodies showed that amyloid beta peptide was mobilized from the
brain and cognitive decline was interrupted. Further studies of passive immunotherapy are urgently
required to confirm these observations.
Introduction
The headline "Minimal benefit is seen in drugs for Alzhe-
imer's disease" summarized an article in the New York
Times concerning drug therapy of Alzheimer's disease [1].
The inescapable conclusion was that present drug therapy
benefits only a very small percentage of the 4.5 million
Americans with Alzheimer's disease patients. This is not
surprising as the goal of today's drugs is to enhance exist-
ing cerebral function in Alzheimer patients and not to
attack the basic causes of their progressive cognitive
decline.
In contrast to today's drug therapy for Alzheimer's disease,
immunotherapy is directed at the neurotoxic amyloid
beta peptide that directly or indirectly leads to cognitive
decline in patients with Alzheimer's disease. Most investi-
gators believe that the accumulation of amyloid beta pep-
tide in the brain of elderly adults is not only a hallmark of
Alzheimer's disease but is the primary cause of cognitive
decline [2]. There is secure evidence from animal studies
and preliminary evidence from patients with sporadic
Alzheimer disease that immunotherapy can block the
accumulation of the neurotoxic amyloid beta peptide in
the brain and cognitive decline in patients with Alzhe-
imer's disease. Reducing the level of amyloid beta peptide
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in the brain can be achieved by decreasing the production
of the amyloid beta peptide and/or by increasing its clear-
ance from the brain. Decreased production of amyloid
beta peptide would follow the inhibition of the beta and
gamma secretases, enzymes that cleave the 40/42 amino
acid amyloid beta peptides from the 770 amino acid
transmembrane amyloid precursor protein (APP) or the
augmentation of the activity of the alpha secretase that
lowers amyloid beta peptide production [3,4]. Although
inhibitors of beta or gamma secretases are known to sup-
press amyloid beta peptide generation from APP in cul-
tured cells, the available inhibitors are too toxic for
clinical use. Furthermore, it is likely that removal of cere-
bral amyloid beta peptide will be necessary to reverse the
accumulated amyloid beta peptide that is already present
at the time when Alzheimer's disease is recognized.
Induction or infusion of anti-amyloid beta peptide anti-
bodies prevents the accumulation of cerebral amyloid
beta peptide from the brain of mouse models of familial
Alzheimer's disease and may work in humans with spo-
radic Alzheimer's disease [6,7]. Even more encouraging
are the reports that immunotherapy reverses cognitive
decline in the mouse models of familial Alzheimer's dis-
ease and may act similarly in elderly humans with spo-
radic Alzheimer's disease [8-10]. This article will review
and place in historical perspective the development of
immunotherapy, in general, and its application to experi-
mental murine models of familial Alzheimer's disease and
to a small number of elderly patients with sporadic Alzhe-
imer's disease so far studied.
Immunotherapy
Immunity was first recognized by the fact that people who
recovered from an infection were often protected from re-
infection. Thus, Thucydides wrote of the Athens epidemic
of plaque that occurred in 430 BC "the same man was
never attacked twice – at least fatally" [11]. Twelve hun-
dred years later, Rhazes wrote that smallpox struck chil-
dren, rarely late in life, and generally only once [12]. The
fact that clinical disease conveyed immunity raised the
question whether the induction of a mild smallpox infec-
tion might protect individuals from this often fatal dis-
ease. Variolization, the inoculation with pustular material
from a smallpox patient, was first reported in the 17th cen-
tury in China to protect from virulent smallpox infection
[13] and brought to wider attention in 1714 by Timoni's
letter to the Royal Society of London reporting on varioli-
zation in Turkey [14]. Despite the clinical efficacy of vari-
olation, the dose of a living, virulent, pathogen was
difficult to control, leading, at times, to serious morbidity
or mortality.
The next advance in immunotherapy followed the realiza-
tion that exposure to a related, less virulent, infectious
organism such as cowpox, protected individuals from the
virulent pathogen, smallpox. In England during the sec-
ond half of the 18th century the link between the fine com-
plexion (no scars of smallpox) of milkmaids and their
exposure to cowpox (vaccinia) was recognized [15]. But it
was Edward Jenner's publication in 1798 that proved that
inoculation with the coxpox, "vaccination", protected sus-
ceptible individuals from small pox [16]. In the years
since Jenner's publication, many vaccines have been
developed to protect humans and animals against infec-
tious diseases [17]. Most vaccine stimulate an immune
response against the infectious microorganisms that cause
disease although some vaccines stimulate an immune
response to toxins they produce [18]. The primary use of
vaccines had been to prevent human disease.
At the end of the 19th century, von Behring and Kitasato
discovered that immunity to diphtheria and tetanus was
conveyed by serum antibodies against the exotoxins of
these bacteria [19]. These investigators, knowing that
serum antibodies conveyed immunity, showed that serum
anti-diphtheria antibodies that had been induced in one
animal could be transferred and, thereby, could cure
another animal showing symptoms of the disease. Thus,
was born the concept of immunotherapy. The clinical
impact of this finding would be great as 50,000 German
children died each year of diphtheria at the end of the 19th
century. The first successful application of immuno-
therapy to humans occurred in 1891 when a child suffer-
ing from diphtheria was cured by an infusion of horse
serum containing anti-diphtheria antibodies. The horse
serum containing anti-toxin antibodies could be lifesav-
ing although many patients, receiving large doses of xeno-
geneic proteins, developed serum sickness resulting from
the patients' immune response to the foreign serum. Dur-
ing the first part of the 20th century passive immuno-
therapy of other infectious diseases including
pneumococal pneumonia entered clinical practice but
was replaced when antibiotics became available during
the second third of the 20th century.
Today, passive immunotherapy is attracting renewed
interest as a new means to treat neurodegenerative, infec-
tious, autoimmune, and neoplastic diseases [7,20,21].
Passive immunotherapy has, thanks largely to remarkable
progress in monoclonal antibody and recombinant DNA
technologies, become one of the hottest fields of thera-
peutics. Humanized or human monoclonal antibodies
have increased the efficacy of passive immunotherapy and
eliminated serum sickness following injection of xenoge-
neic serum. Now passive immunotherapy has been devel-
oped for patients with chronic diseases including
atherosclerotic, neoplastic, and neurodegenerative dis-
eases.Immunity & Ageing 2004, 1:2 http://www.immunityageing.com/content/1/1/2
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Active Immunotherapy of Alzheimer's Disease
Immunotherapy of Alzheimer's disease followed the
development of a mouse model of familial Alzheimer's
disease. In 1995, an APP-transgenic mouse expressing a
mutant, human APP gene isolated from a Swedish family
with inherited Alzheimer's disease was developed [22].
These mice develop cerebral diffuse deposits of amyloid
peptide and amyloid plaques by middle age and were,
therefore, a useful model of familial Alzheimer's disease.
Four years later, Schenk and his colleagues reported that
repeated immunization of such mice with amyloid beta
peptide prevented or reversed accumulation of amyloid
deposits in the brain of these mice [6]. Despite the dra-
matic effects of active immunotherapy on cerebral his-
topathology in APP-transgenic mice, the key question –
did immunotherapy prevent cognitive decline – remained
to be answered. Eighteen months later it was reported that
the cognitive decline seen in the APP-transgenic mice was
blocked by active immunization [23-25]. No toxicity was
observed following active immunization of APP-trans-
genic mice, despite some concern that the administration
of the neurotoxic amyloid beta peptide might cause unto-
ward effects [26].
These observations offered great promise for the treat-
ment of patients with familial Alzheimer's disease and,
perhaps, elderly patients with sporadic Alzheimer's dis-
ease. A clinical trial of active immunization of elderly
patients with sporadic Alzheimer's disease was organized
and initiated in 2001. However, there were reasons to
question whether the benefits seen in a middle-aged mice
model of familial Alzheimer's disease could be directly
extrapolated to elderly patients with sporadic Alzheimer's
disease.
First of all, aging is associated with a decreasing immune
response [27]. Thus, active immunization with influenza
or tetanus vaccines induces less protective immunity in
old than young persons or experimental animals. It was
reported that a large percentage of old mice and elderly
humans following active immunization with amyloid
beta peptide did not generate a robust anti-amyloid beta
peptide antibody response [9,28]. Secondly, active immu-
nization of elderly humans and old mice stimulates an
increase in autoimmune responses despite the lower
immune response to the foreign antigen [29].
The clinical trial of active immunization of patients with
Alzheimer's disease with amyloid beta peptide, started in
2001, was stopped a year later after 4 patients in the
actively immunized group developed sterile meningoen-
cephalitis [30]. Approximately 6% of the 298 actively
immunized Alzheimer's disease patients eventually devel-
oped sterile encephalitis. One patient with sporadic
Alzheimer's disease died 12 months after the last immuni-
zation with amyloid beta peptide from a pulmonary
embolus. Post-mortem examination of the brain in this
patient revealed CD4+ T cells in a perivascular distribu-
tion [31]. While neither the function nor the specificity of
the T cells infiltrating the brain was determined, it is pos-
sible that the age-associated tendency to generate autoim-
mune reactions led these patients to generate autoreactive
CD4+T cells that entered the brain and contributed to
encephalitis.
No comprehensive report of the clinical study of active
immunization has yet been published but oral presenta-
tions and published results from a subset of actively
immunized Alzheimer's disease patients have provided
some information [9]. It appears that: (i) all patients with
sterile encephalitis had been actively immunized with
amyloid beta peptide; (ii) there was no correlation
between the level of serum anti-amyloid beta peptide
antibodies and risk of sterile encephalitis; (iii) certain
patients with sterile encephalitis had no detectable anti-
amyloid beta peptide antibodies in serum; (iv) one-half of
the elderly patients with sporadic Alzheimer's disease who
were immunized with amyloid beta peptide did not gen-
erate significant titers of anti-amyloid beta peptide anti-
bodies; and finally, (v) in a subset of patients with
sporadic Alzheimer's disease, those patients who gener-
ated significant levels of serum anti-amyloid beta peptide
antibodies had little or no cognitive decline during the
year of observation following active immunotherapy.
In summary, active immunization with amyloid beta pep-
tide in elderly patients with Alzheimer's disease appears to
be less effective and more toxic than in the middle-aged
APP-transgenic mouse model of familial Alzheimer's dis-
ease. These differences may reflect the greater age of the
patients with sporadic Alzheimer's disease and the
decreased antibody responses to vaccines and the para-
doxical increase in autoimmune responses in the elderly.
Passive Immunotherapy of Alzheimer's Disease
Administration of anti-amyloid beta peptide antibodies
would bypass immune senescence and would not be
expected to lead to T cell-mediated encephalitis. Further-
more, anti-amyloid beta peptide antibodies not only dis-
solved aggregates of amyloid beta peptide in vitro but also
inhibited aggregated amyloid beta peptide-mediated cyto-
toxicity in vitro [32]. In vivo, passive immunotherapy of
APP-transgenic mice with anti-amyloid beta peptide anti-
bodies prevented or reversed cerebral amyloid deposition
depending on whether treatment was begun before or
after cerebral amyloid deposition had occurred [7]. It has
been reported that passive immunotherapy of APP-trans-
genic mice prevented age-associated cognitive decline on
in the APP-transgenic mice after a 6 week course of treat-
ment with anti-amyloid beta peptide antibodies evenImmunity & Ageing 2004, 1:2 http://www.immunityageing.com/content/1/1/2
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before there was any detectable decrease in cerebral amy-
loid plaque number [33]. Preliminary clinical studies
showed that infusing a preparation of human intravenous
immunoglobulin (IVIg) containing anti-amyloid beta
peptide antibodies into 6 elderly patients with sporadic
Alzheimer's disease showed significant cognitive
improvement during the 6 months of therapy [10]. Elan
announced that a phase 1 clinical study of passive immu-
notherapy with humanized monoclonal anti-amyloid
beta peptide antibody in patients with mild to moderate
Alzheimer's disease had been started at the end of 2003
http://www.elan.com.
The potential benefit of anti-amyloid beta peptide anti-
bodies in humans with sporadic Alzheimer's disease was
also inferred from studies of cognitive function in a subset
of actively immunized patients with Alzheimer's disease
[9]. In these patients, there was a direct correlation
between the level of serum anti-amyloid beta peptide
antibodies and cognitive function one year after active
immunization. Thus, the patients with the highest serum
levels of anti-amyloid beta peptide had little or no cogni-
tive decline while cognitive function declined markedly in
the nearly 50% of patients who generated little or no
detectable serum anti-amyloid beta peptide antibodies
after active immunization.
Passive immunotherapy of Alzheimer's disease would
require repeated administration of anti-amyloid beta pep-
tide antibodies. For this reason, human anti-amyloid beta
peptide antibodies should be used to prevent an immune
response to the currently available murine monoclonal
immunoglobulins. Several methods are known to obtain
human anti-amyloid beta peptide antibodies: (i) purifica-
tion of specific antibodies from human IVIg; (ii) human-
ization of murine anti-amyloid beta peptide antibodies by
replacing framework portions of the murine anti-amyloid
beta peptide antibodies with human framework
sequences using recombinant DNA technology [34]; (iii)
generation of human monoclonal anti-amyloid beta pep-
tide antibodies in vitro by human immunoglobulin phage
library display techniques or in vivo by immunization of
mice whose immunoglobulin loci have been replaced by
human Ig genes [34].
Human IVIg, purified from human plasma, was initially
developed as replacement therapy for immunodeficient
patients but IVIg has also been shown to be effective ther-
apy in patients with a variety of autoimmune diseases
[35]. Recently, we and others have demonstrated that
human serum and IVIg have a significant quantity of
human anti-amyloid beta peptide antibodies [36,37].
Such polyclonal human anti-amyloid beta peptide anti-
body preparations inhibit amyloid beta peptide-induced
neurotoxicity in vitro.
There is no evidence that anti-amyloid beta peptide anti-
bodies induce sterile encephalitis, observed following
passive immunization of several strains of APP-transgenic
mice or in the small number of elderly patients with
Alzheimer's disease. However, it may be premature to
conclude that passive immunotherapy with anti-amyloid
beta peptide antibodies does not induce cerebral pathol-
ogy. It should be remembered that most of the APP-trans-
genic mice strains tested do not develop amyloid vascular
deposits (congophilic angiopathy) that occurs in elderly
patients with Alzheimer's disease. It was reported that
infusion of murine anti-amyloid beta peptide mono-
clonal antibodies specific for the N-terminal epitope of
the amyloid beta peptide into a strain of APP-transgenic
mice, which develop congophilic angiopathy, cerebral
hemorrhage was observed [38]. This untoward effect
appears to depend upon the epitope specificity of the anti-
amyloid beta peptide antibodies.
The Choice of Anti-amyloid Beta Peptide 
Antibodies for Alzheimer's Disease
Pre-clinical data and inferences drawn from immuno-
therapy in patients with sporadic Alzheimer's disease sug-
gest that passive immunotherapy with anti-amyloid beta
peptide antibodies is preferable to active immunotherapy
for the treatment of elderly patients with sporadic Alzhe-
imer's disease. However, which anti-amyloid beta peptide
antibodies would have greatest therapeutic efficacy and
least risk of untoward effects for patients with Alzheimer's
disease remains to be determined. However, there is gen-
eral agreement that anti-amyloid beta peptide antibodies
to be administered repeatedly to patients should not stim-
ulate an antibody response to the infused immunoglobu-
lin. There is evidence that humans not only can make
immune response to therapeutic antibodies but that such
immune responses compromise the action of the thera-
peutic antibodies [39]. To date, the only human anti-amy-
loid beta peptide antibodies reported to improve
cognitive function in elderly patients with sporadic Alzhe-
imer's disease are those contained in human IVIg [11]. In
contrast to preparations containing polyclonal human
anti-amyloid beta antibodies, several laboratories have
produced humanized anti-amyloid beta peptide antibod-
ies including the Elan preparation now in phase I trial. It
has not been reported whether this humanized anti-amy-
loid beta peptide antibody is active in APP-transgenic
mice. The therapeutic efficacy of candidate human anti-
amyloid beta peptide antibodies can be compared by
measuring their capacity to decrease or reverse cerebral
amyloid beta peptide accumulation and cognitive decline
in RAG-2-deficient, APP-transgenic mice. We have bred
these mice that lack lymphocytes and are incapable of
generating an immune response to the human anti-amy-
loid beta peptide antibodies to test antibodies considered
for immunotherapy of Alzheimer's disease.Immunity & Ageing 2004, 1:2 http://www.immunityageing.com/content/1/1/2
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If the therapeutic benefit of polyclonal human anti-amy-
loid beta peptide antibodies is confirmed, it remains to be
determined which antibody or antibodies are responsible
for the therapeutic effect. Whether a single monoclonal
antibody will be effective in humans as it has been in APP-
transgenic mice is not certain. In some infectious diseases,
a single monoclonal antibody has not been less protective
than a mixture of several monoclonal antibodies [40].
Thus, while each antibody specificity in polyclonal
human anti-amyloid beta peptide antibodies may be at a
lower concentration than that of a monoclonal antibody,
the synergistic effect of multiple antibody specificities
may have advantage.
Monoclonal anti-amyloid beta peptide antibodies are
known to differ in their fine specificity: isotype, affinity, as
well as epitope, aggregate, and Fc specificity [41]. Whether
it will be possible to choose an anti-amyloid beta peptide
monoclonal antibody based on these characteristics is far
from certain. It is likely that testing in immune deficient
APP-transgenic mouse would be performed prior to the
treatment of patients with Alzheimer's disease.
Monoclonal anti-amyloid beta peptide have different spe-
cificities. There are three major epitopes on the amyloid
beta peptide: (i) antibodies to the N-terminal epitope
(amino acids 1–6) of the amyloid peptide bind to aggre-
gated amyloid beta peptide in vitro as well as cerebral and
vascular deposits in vivo and APP (ii) antibodies specific
for the central region (amino acids 15–25) of the amyloid
peptide bind to APP but not to aggregated amyloid beta
peptide in vitro, amyloid plaques or vascular amyloid
deposits (iii) antibodies specific for the C-terminal region
have been less well studied but reported to lack a thera-
peutic effect in APP-transgenic mice. This may be the rea-
son why the N-terminal-specific anti-amyloid beta
peptide antibodies but not central region-specific anti-
bodies cause cerebral hemorrhage presumably from ves-
sels with amyloid beta deposits [42].
Anti-amyloid beta peptide antibodies that differ in
epitope and Fc specificities, dissolve cerebral amyloid
plaques and block cognitive decline in APP-transgenic
mice [41]. Anti-amyloid beta peptide antibodies, specific
for the N-terminal region of the amyloid peptide, are
reported to enter the brain, bind to cerebral amyloid
plaques, dissolve the plaque, and mediate Fc-mediated
endocytosis followed by catabolism of the amyloid beta
peptide within glial cells [7]. However, the Fc-mediated
pathway is not the only route to the dissolution of amy-
loid plaques. Direct application of anti-amyloid beta pep-
tide antibodies that bind to amyloid plaques but do not
express the Fc region of the molecule dissolve cerebral
amyloid plaques [43]. Furthermore, anti-amyloid peptide
antibodies dissolve amyloid plaques in APP-transgenic
mice that do not express Fc receptors.
Surprisingly, treatment of APP-transgenic mice with anti-
amyloid beta peptide antibodies specific for the central
region of the amyloid peptide that do not stain cerebral
amyloid plaques ex vivo and were not detectable within
the brain also cleared cerebral amyloid peptide and
plaques [33]. A novel explanation for the mechanism of
action of anti-amyloid beta peptide antibodies that do not
enter the brain. The "peripheral sink" hypothesis suggests
that cerebral amyloid beta peptide in all its forms (mono-
mer, oligomer, fibrils) are in equilibrium with amyloid
beta peptide in the blood and, that anti-amyloid peptide
antibodies, which cannot cross the blood-brain barrier,
deplete cerebral amyloid beta peptide by its mobilization
into the blood. It was shown that within a few hours of
administering central region-specific anti-amyloid beta
peptide antibodies, which do not enter the brain, the level
of amyloid beta peptide in the blood increases as much as
1000 fold. Furthermore, the magnitude of the increase in
total amyloid beta peptide levels in the blood following a
single injection of anti-amyloid beta peptide antibody is a
surrogate marker of cerebral amyloid beta peptide load
[44]. Thus, it appears that similar effects – decreased cere-
bral amyloid load and cognitive loss can occur following
treatment of APP-transgenic mice with different anti-amy-
loid beta peptide monoclonal antibodies by central (entry
into the brain) or peripheral (entry into the blood) mech-
anisms.
Both N-terminal-specific and central region-specific anti-
amyloid beta peptide antibodies but not C-terminal-spe-
cific anti-amyloid beta peptide antibodies also bind to
APP the ubiquitous transmembrane cellular protein. C-
terminal-specific anti-amyloid beta peptide antibodies
can distinguish between amyloid beta 1–40 and 1–42
peptide. As amyloid beta 1–42 peptide is more neurotoxic
peptide and forms the nidus of cerebral amyloid plaques
antibodies to this amyloid beta peptide might be the most
effective antibody for passive immunotherapy as they tar-
get the most pathogenic form of the amyloid beta peptide
without binding to APP or the less pathogenic amyloid
beta 1–40 peptide. However, the C-terminal specific anti-
amyloid beta peptide antibodies have been reported not
to clear cerebral amyloid beta peptide [41]. Recently, it
has been reported that a C-terminal specific anti-amyloid
beta peptide antibody does clear amyloid plaques [45].
Finally, there is considerable interest in the greater neuro-
toxicity of soluble amyloid beta peptide oligomers than
either the amyloid beta monomers or fibrils [46]. If this
proves to be case, it would be important to test the thera-
peutic efficacy of monoclonal antibodies to amyloid beta
peptide oligomers in APP-transgenic mice [47].Immunity & Ageing 2004, 1:2 http://www.immunityageing.com/content/1/1/2
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Conclusion
Passive immunotherapy of sporadic Alzheimer's disease
offers the potential of reversing the pathologic accumula-
tion of cerebral amyloid beta peptide. To date the only
preparation of human anti-amyloid beta peptide antibod-
ies that have been reported to reverse cognitive defects in
patients with sporadic Alzheimer's disease are polyclonal
anti-amyloid beta peptide antibodies contained in human
IVIg. Selection of human anti-amyloid beta peptide anti-
bodies for clinical trial can be tested for therapeutic effect
in vivo by their treatment of immunodeficient APP-trans-
genic mice.
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